Serotonin modulator and stimulator

A serotonin modulator and stimulator (SMS), sometimes referred to more simply as a serotonin modulator, is a type of drug with a multimodal action specific to the serotonin neurotransmitter system. To be precise, SMSs simultaneously modulate one or more serotonin receptors and inhibit the reuptake of serotonin. The term was created to describe the mechanism of action of the serotonergic antidepressant vortioxetine, which acts as a serotonin reuptake inhibitor (SRI), agonist of the 5-HT_1A receptor, and antagonist of the 5-HT₃ and 5-HT₇ receptors.^[1]^[2]^[3] However, it can also technically be applied to vilazodone, which is an antidepressant as well and acts as an SRI and 5-HT_1A receptor partial agonist.^[4]

SMSs were developed because there are many different subtypes of serotonin receptors (at least 15 in total are currently known) and not all of these receptors appear to be involved in the antidepressant effects of SRIs.^[5] Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT_1A autoreceptors and 5-HT₇ receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.^[5] As such, a drug which combines the actions of, say, an SRI, 5-HT_1A partial agonism, and 5-HT₇ receptor antagonism, could, in theory, have the potential to prove more effective than pure SRIs. Alternatively, antagonism of 5-HT₃ – a receptor that is involved in the regulation of nausea, vomiting, and the gastrointestinal tract – could counteract the undesirable increase in activation of this receptor mediated by SRIs, thereby potentially improving tolerability.^[6]

An alternative term is serotonin partial agonist/reuptake inhibitor (SPARI), which can be applied only to vilazodone.^[7]

It is similar to the marketing strategy used for the drug brexpiprazole, labeling it as a "serotonin-dopamine activity modulator" or 'SDAM'.^[8]

References

^ Goldenberg MM (November 2013). "Pharmaceutical approval update". P T. 38 (11): 705–7. PMC 3875258. PMID 24391391.
^ American Pharmacists Association (2013). "Vortioxetine: Atypical antidepressant".
^ Los Angeles Times (2013). "FDA approves a new antidepressant: Brintellix". Los Angeles Times.
^ Hughes ZA, Starr KR, Langmead CJ, et al. (March 2005). "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone". European Journal of Pharmacology. 510 (1–2): 49–57. doi:10.1016/j.ejphar.2005.01.018. PMID 15740724.
^ ^a ^b Artigas, Francesc (2015). "Developments in the field of antidepressants, where do we go now?". European Neuropsychopharmacology. 25 (5): 657–670. doi:10.1016/j.euroneuro.2013.04.013. hdl:10261/89228. ISSN 0924-977X. PMID 23706576. S2CID 25524744.
^ Chad E. Beyer; Stephen M. Stahl (20 May 2010). Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Cambridge University Press. pp. 19–. ISBN 978-0-521-76058-4.
^ Muntner, Stephen M. Stahl ; with illustrations by Nancy (2013). Stahl's essential psychopharmacology : neuroscientific basis and practical application (4th ed.). Cambridge: Cambridge University Press. ISBN 978-1107686465.{{cite book}}: CS1 maint: multiple names: authors list (link)
^ Yoshimi, Noriko; Fujita, Yuko; Ohgi, Yuta; Futamura, Takashi; Kikuchi, Tetsuro; Hashimoto, Kenji (2014). "Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors". Pharmacology Biochemistry and Behavior. 124: 245–249. doi:10.1016/j.pbb.2014.06.008. ISSN 1873-5177. PMID 24955861. S2CID 42990883.

[pmid24391391-1] Goldenberg MM (November 2013). "Pharmaceutical approval update". P T. 38 (11): 705–7. PMC 3875258. PMID 24391391.

[AmerPharmAssoc2013-2] American Pharmacists Association (2013). "Vortioxetine: Atypical antidepressant".

[LATimes2013-3] Los Angeles Times (2013). "FDA approves a new antidepressant: Brintellix". Los Angeles Times.

[pmid15740724-4] Hughes ZA, Starr KR, Langmead CJ, et al. (March 2005). "Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone". European Journal of Pharmacology. 510 (1–2): 49–57. doi:10.1016/j.ejphar.2005.01.018. PMID 15740724.

[Artigas2015-5] Artigas, Francesc (2015). "Developments in the field of antidepressants, where do we go now?". European Neuropsychopharmacology. 25 (5): 657–670. doi:10.1016/j.euroneuro.2013.04.013. hdl:10261/89228. ISSN 0924-977X. PMID 23706576. S2CID 25524744.

[BeyerStahl2010-6] Chad E. Beyer; Stephen M. Stahl (20 May 2010). Next Generation Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Cambridge University Press. pp. 19–. ISBN 978-0-521-76058-4.

[7] Muntner, Stephen M. Stahl ; with illustrations by Nancy (2013). Stahl's essential psychopharmacology : neuroscientific basis and practical application (4th ed.). Cambridge: Cambridge University Press. ISBN 978-1107686465.{{cite book}}: CS1 maint: multiple names: authors list (link)

[8] Yoshimi, Noriko; Fujita, Yuko; Ohgi, Yuta; Futamura, Takashi; Kikuchi, Tetsuro; Hashimoto, Kenji (2014). "Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors". Pharmacology Biochemistry and Behavior. 124: 245–249. doi:10.1016/j.pbb.2014.06.008. ISSN 1873-5177. PMID 24955861. S2CID 42990883.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

See also

References